Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to $500000.0.

  • RedHill Biopharma's Total Non-Current Liabilities fell 3150.68% to $500000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $500000.0, marking a year-over-year decrease of 3150.68%. This contributed to the annual value of $503000.0 for FY2024, which is 4944.72% down from last year.
  • Per RedHill Biopharma's latest filing, its Total Non-Current Liabilities stood at $500000.0 for Q2 2025, which was down 3150.68% from $503000.0 recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Total Non-Current Liabilities peaked at $94.9 million during Q2 2021, and registered a low of $500000.0 during Q2 2025.
  • For the 5-year period, RedHill Biopharma's Total Non-Current Liabilities averaged around $23.9 million, with its median value being $3.4 million (2023).
  • In the last 5 years, RedHill Biopharma's Total Non-Current Liabilities crashed by 103.22% in 2021 and then plummeted by 8986.35% in 2023.
  • Over the past 5 years, RedHill Biopharma's Total Non-Current Liabilities (Quarter) stood at $90.8 million in 2021, then crashed by 89.19% to $9.8 million in 2022, then tumbled by 89.86% to $995000.0 in 2023, then tumbled by 49.45% to $503000.0 in 2024, then fell by 0.6% to $500000.0 in 2025.
  • Its last three reported values are $500000.0 in Q2 2025, $503000.0 for Q4 2024, and $730000.0 during Q2 2024.